Aberdeen Group discloses 8.24M Immunic (IMUX) shares held for clients

Rhea-AI Filing Summary

Immunic, Inc. received an amended Schedule 13G/A from Aberdeen Group plc and its subsidiary abrdn Inc. reporting a significant ownership position in the company’s common stock.

The filing shows beneficial ownership of 8,243,941 Immunic common shares, representing 6.85% of the class as of 12/31/2025. Both Aberdeen Group plc and abrdn Inc. report shared power to vote and dispose of these shares, with no sole voting or dispositive power.

The securities are stated to be acquired and held in the ordinary course of business, and not for the purpose of changing or influencing control of Immunic. Aberdeen Group plc is identified as the parent company, with abrdn Holdings Limited as intermediate holding company for abrdn Inc.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

IMMUNIC, INC.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

4525EP101

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 4525EP101

1

Names of Reporting Persons

Aberdeen Group plc

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 8,243,941.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 8,243,941.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,243,941.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.85 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 4525EP101

1

Names of Reporting Persons

abrdn Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 8,243,941.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 8,243,941.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,243,941.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.85 %

12

Type of Reporting Person (See Instructions)

CO, IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: IMMUNIC, INC.
(b)	Address of issuer's principal executive offices: 1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK, NEW YORK 10036
Item 2.
(a)	Name of person filing: Aberdeen Group plc abrdn Inc.
(b)	Address or principal business office or, if none, residence: Aberdeen Group plc: 1 George Street Edinburgh, United Kingdom EH2 2LL abrdn Inc. 1900 Market Street Suite 200. Philadelphia, PA 19103
(c)	Citizenship: Aberdeen Group plc - UNITED KINGDOM abrdn Inc. - UNITED STATES
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 4525EP101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 8,243,941
(b)	Percent of class: 6.85 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Aberdeen Group plc - 0 abrdn Inc. - 0
	(ii) Shared power to vote or to direct the vote: Aberdeen Group plc - 8,243,941 abrdn Inc. - 8,243,941
	(iii) Sole power to dispose or to direct the disposition of: Aberdeen Group plc - 0 abrdn Inc. - 0
	(iv) Shared power to dispose or to direct the disposition of: Aberdeen Group plc - 8,243,941 abrdn Inc. - 8,243,941
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Aberdeen Group plc

Signature:	F.Osei
Name/Title:	Frederic Osei, Major Shareholding Reporting Analyst
Date:	12/31/2025

abrdn Inc.

Signature:	F.Osei
Name/Title:	Frederic Osei, Major Shareholding Reporting Analyst
Date:	12/31/2025

Exhibit Information

Aberdeen Group plc abrdn Holdings Limited abrdn Inc. Aberdeen Group plc is the parent company. abrdn Holdings Limited is the intermediate holding company for abrdn Inc. abrdn Inc. beneficially owns on behalf of our underlying clients 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G.

FAQ

What ownership stake in Immunic (IMUX) is reported by Aberdeen Group?

Aberdeen Group plc and abrdn Inc. report beneficial ownership of 8,243,941 Immunic common shares, representing 6.85% of the outstanding class as of December 31, 2025. This makes them a significant institutional shareholder under U.S. securities reporting rules.

Who are the reporting persons in the Immunic (IMUX) Schedule 13G/A?

The reporting persons are Aberdeen Group plc and its subsidiary abrdn Inc. Aberdeen Group plc is the parent company, abrdn Holdings Limited is the intermediate holding company, and abrdn Inc. holds the shares beneficially on behalf of underlying clients.

How many Immunic (IMUX) shares does abrdn Inc. report holding?

abrdn Inc. reports beneficial ownership of 8,243,941 Immunic common shares with shared voting and shared dispositive power. It has no sole voting or sole dispositive power over these shares, which are held on behalf of underlying clients as disclosed in the exhibit.

Does Aberdeen’s Immunic (IMUX) filing indicate an intent to influence control?

The certification states the securities were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of Immunic. It also states they are not held in connection with any control-related transaction, aside from specified nomination activities.

What percentage of Immunic (IMUX) does Aberdeen Group’s stake represent?

The reported beneficial ownership of 8,243,941 Immunic common shares represents 6.85% of the company’s outstanding common stock. This percentage meets the threshold that requires institutional investors to file a Schedule 13G/A with the U.S. Securities and Exchange Commission.

What voting and dispositive powers are reported over Immunic (IMUX) shares?

Both Aberdeen Group plc and abrdn Inc. report zero sole voting and zero sole dispositive power over Immunic shares. They each report shared voting power and shared dispositive power over 8,243,941 common shares, reflecting their role managing assets for underlying clients.